Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy - comparison with late enhancement quantification

Magnetic Resonance Imaging

Volumn 33, Issue 6, 2015, Pages 718-724

  Małek, Łukasz A ^a   Werys, Konrad ^a,b   Kłopotowski, Mariusz ^a   Śpiewak, Mateusz ^a   Miłosz Wieczorek, Barbara ^a   Mazurkiewicz, Łukasz ^a   Petryka Mazurkiewicz, Joanna ^a   Marczak, Magdalena ^a   Witkowski, Adam ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Fibrosis; Hypertrophic cardiomyopathy; Late gadolinium enhancement; Magnetic resonance; Native T1 mapping; ShMOLLI

Indexed keywords

GADOBUTROL; CONTRAST MEDIUM; GADOLINIUM;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LATE GADOLINIUM ENHANCEMENT; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; CARDIAC MUSCLE; CINE MAGNETIC RESONANCE IMAGING; COMPARATIVE STUDY; FIBROSIS; IMAGE ENHANCEMENT; MIDDLE AGED; PATHOLOGY;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 84930925573     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2015.04.001     Document Type: Article

References (33)

1. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
2. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014, 35:2733-2779. Authors/Task Force members.
3. Ho C.Y., López B., Coelho-Filho O.R., Lakdawala N.K., Cirino A.L., Jarolim P., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010, 363:552-563.
4. Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
5. Bruder O., Wagner A., Jensen C.J., Schneider S., Ong P., Kispert E.M., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
6. Rubinsthein R., Glockner J.F., Ommen S.R., Araoz P.A., Ackerman M.J., Sorajja P., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 33:51-58.
7. O'Hanlon R., Grasso A., Roughton M., Moon J.C., Clark S., Wage R., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
8. Rudolph A., Abdel-Aty H., Bohl S., Boyé P., Zagrosek A., Dietz R., et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009, 53:284-291.
9. Puntmann V.O., Jahnke C., Gebker R., Schnackenburg B., Fox K.F., Fleck E., et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol 2010, 106:1016-1022.
10. Noureldin R.A., Liu S., Nacif M.S., Judge D.P., Halushka M.K., Abraham T.P., et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012, 14:17.
11. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
12. Śpiewak M., Małek Ł.A., Miśko J., Chojnowska L., Miłosz B., Kłopotowski M., et al. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 2010, 74:e149-e153.
13. Harrigan C.J., Peters D.C., Gibson C.M., Maron B.J., Manning W.J., Maron M.S., et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 2011, 258:128-133.
14. Maron M.S., Appelbaum E., Harrigan C.J., Buros J., Gibson C.M., Hanna C., et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008, 1:184-191.
15. Chan R.H., Maron B.J., Olivotto I., Pencina M.J., Assenza G.E., Haas T., et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014, 130:484-495.
16. Thomsen H.S., Morcos S.K., Almén T., Bellin M.F., Bertolotto M., Bongartz G., et al. ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013, 23:307-318.
17. Parsai C., O'Hanlon R., Prasad S.K., Mohiaddin R.H. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012, 14:54.
18. Moon J.C., Messroghli D.R., Kellman P., Piechnik S.K., Robson M.D., Ugander M., et al. Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013, 15:92.
19. Piechnik S.K., Ferreira V.M., Dall'Armellina E., Cochlin L.E., Greiser A., Neubauer S., et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010, 12:69.
20. Moravsky G., Ofek E., Rakowski H., Butany J., Williams L., Ralph-Edwards A., et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 2013, 6:587-596.
21. Puntmann V.O., Voigt T., Chen Z., Mayr M., Karim R., Rhode K., et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013, 6:475-484.
22. Fontana M., Banypersad S.M., Treibel T.A., Maestrini V., Sado D.M., White S.K., et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014, 7:157-165.
23. Dass S., Suttie J.J., Piechnik S.K., Ferreira V.M., Holloway C.J., Banerjee R., et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 2012, 5:726-733.
24. Ferreira V.M., Piechnik S.K., Dall'Armellina E., Karamitsos T.D., Francis J.M., Choudhury R.P., et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012, 14:42.
25. Ferreira V.M., Piechnik S.K., Dall'Armellina E., Karamitsos T.D., Francis J.M., Ntusi N., et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson 2014, 16:36.
26. Bull S., White S.K., Piechnik S.K., Flett A.S., Ferreira V.M., Loudon M., et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 2013, 99:932-937.
27. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012, 5:370-377.
28. Ismail T.F., Jabbour A., Gulati A., Mallorie A., Raza S., Cowling T.E., et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 2014, 100:1851-1858.
29. Hanneman K., Crean A.M., Williams L., Moshonov H., James S., Jiménez-Juan L., et al. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy. J Thorac Imaging 2014, 29:331-339.
30. Hen Y., Iguchi N., Utanohara Y., Takada K., Machida H., Takayama M., et al. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 2014, 78:929-937.
31. Flett A.S., Hasleton J., Cook C., Hausenloy D., Quarta G., Ariti C., et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011, 4:150-156.
32. Dabir D., Child N., Kalra A., Rogers T., Gebker R., Jabbour A., et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2014, 16:69.
33. Piechnik S.K., Ferreira V.M., Lewandowski A.J., Ntusi N.A., Banerjee R., Holloway C., et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson 2013, 15:13.